Literature DB >> 30326280

Bendamustine with Total Body Irradiation Limits Murine Graft-versus-Host Disease in Part Through Effects on Myeloid-Derived Suppressor Cells.

Jessica Stokes1, Emely A Hoffman1, Megan S Molina2, Jelena Eremija1, Nicolas Larmonier3, Yi Zeng4, Emmanuel Katsanis5.   

Abstract

Graft-versus-host disease (GVHD) remains a significant challenge in allogeneic hematopoietic cell transplantation (HCT). An underinvestigated strategy to reduce GVHD is the modification of the preparative conditioning regimen. In the present study, we aimed to evaluate GVHD associated with bendamustine (BEN) conditioning in conjunction with total body irradiation (TBI) as an alternative to the standard myeloablative regimen of cyclophosphamide (CY) and TBI. We demonstrate that BEN-TBI conditioning, although facilitating complete donor chimerism, results in significantly less GVHD compared with CY-TBI. In BEN-TBI-conditioned mice, suppressive CD11b+Gr-1high myeloid cells are increased in the blood, bone marrow, spleen, and intestines. When Gr-1high cells are depleted before transplantation, the beneficial effects of BEN-TBI are partially lost. Alternatively, administration of granulocyte colony-stimulating factor, which promotes CD11b+Gr-1+ myeloid cell expansion, is associated with a trend toward increased survival in BEN-TBI-conditioned mice. These findings indicate a potential role of myeloid-derived suppressor cells in the mechanism by which BEN allows engraftment with reduced GVHD. BEN-TBI conditioning may present a safer alternative to CY-TBI conditioning for allogeneic HCT.
Copyright © 2018 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bendamustine; Graft-versus-host disease; Myeloid-derived suppressor cells

Mesh:

Substances:

Year:  2018        PMID: 30326280      PMCID: PMC7571287          DOI: 10.1016/j.bbmt.2018.10.009

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  74 in total

1.  Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy.

Authors:  H Joachim Deeg; Margaret O'Donnell; Jakub Tolar; Rajni Agarwal; Richard E Harris; Stephen A Feig; Mary C Territo; Robert H Collins; Peter A McSweeney; Edward A Copelan; Shakila P Khan; Ann Woolfrey; Barry Storer
Journal:  Blood       Date:  2006-05-09       Impact factor: 22.113

2.  Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group.

Authors:  Manuela A Bergmann; Maria E Goebeler; Michael Herold; Bertold Emmerich; Martin Wilhelm; Corinna Ruelfs; Lothar Boening; Michael J Hallek
Journal:  Haematologica       Date:  2005-10       Impact factor: 9.941

3.  Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma.

Authors:  Gaetano Corazzelli; Francesco Angrilli; Alfonso D'Arco; Felicetto Ferrara; Pellegrino Musto; Attilio Guarini; Maria Christina Cox; Caterina Stelitano; Sergio Storti; Emilio Iannitto; Simona Falorio; Catello Califano; Alfonso Amore; Manuela Arcamone; Rosaria De Filippi; Antonio Pinto
Journal:  Br J Haematol       Date:  2012-11-20       Impact factor: 6.998

4.  The Granulocyte Progenitor Stage Is a Key Target of IRF8-Mediated Regulation of Myeloid-Derived Suppressor Cell Production.

Authors:  Colleen S Netherby; Michelle N Messmer; Lauren Burkard-Mandel; Sean Colligan; Austin Miller; Eduardo Cortes Gomez; Jianmin Wang; Michael J Nemeth; Scott I Abrams
Journal:  J Immunol       Date:  2017-03-29       Impact factor: 5.422

5.  Sensitive LC-MS/MS Method for the Simultaneous Determination of Bendamustine and its Active Metabolite, γ-Hydroxybendamustine in Small Volume Mice and Dog Plasma and its Application to a Pharmacokinetic Study in Mice and Dogs.

Authors:  Devaraj V Chandrashekar; Ponnayyan S Suresh; Rajnish Kumar; Ravi Kanth Bhamidipati; Ramesh Mullangi; Wolfgang Richter; Nuggehally R Srinivas
Journal:  Drug Res (Stuttg)       Date:  2017-05-30

6.  A Phase 3, Randomized, Placebo-controlled Trial of Filgrastim in Patients with Haematological Malignancies Undergoing Matched-related Allogeneic Bone Marrow Transplantation.

Authors:  Peter Ernst; Andrea Bacigalupo; Olle Ringdén; Tapani Ruutu; Hans J Kolb; Susan Lawrinson; Tomas Skacel
Journal:  Arch Drug Inf       Date:  2008-12

7.  A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission.

Authors:  David I Marks; Stephen J Forman; Karl G Blume; Waleska S Pérez; Daniel J Weisdorf; Armand Keating; Robert Peter Gale; Mitchell S Cairo; Edward A Copelan; John T Horan; Hillard M Lazarus; Mark R Litzow; Philip L McCarthy; Kirk R Schultz; David D Smith; Michael E Trigg; Mei-Jie Zhang; Mary M Horowitz
Journal:  Biol Blood Marrow Transplant       Date:  2006-04       Impact factor: 5.742

8.  Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation.

Authors:  Jessica Stokes; Emely A Hoffman; Yi Zeng; Nicolas Larmonier; Emmanuel Katsanis
Journal:  Br J Haematol       Date:  2016-03-31       Impact factor: 6.998

9.  Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage.

Authors:  Lukas Schwab; Luise Goroncy; Senthilnathan Palaniyandi; Sanjivan Gautam; Antigoni Triantafyllopoulou; Attila Mocsai; Wilfried Reichardt; Fridrik J Karlsson; Sabarinath V Radhakrishnan; Kathrin Hanke; Annette Schmitt-Graeff; Marina Freudenberg; Friederike D von Loewenich; Philipp Wolf; Franziska Leonhardt; Nicoleta Baxan; Dietmar Pfeifer; Oliver Schmah; Anne Schönle; Stefan F Martin; Roland Mertelsmann; Justus Duyster; Jürgen Finke; Marco Prinz; Philipp Henneke; Hans Häcker; Gerhard C Hildebrandt; Georg Häcker; Robert Zeiser
Journal:  Nat Med       Date:  2014-05-18       Impact factor: 53.440

10.  Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer.

Authors:  Srinivas Nagaraj; Kapil Gupta; Vladimir Pisarev; Leo Kinarsky; Simon Sherman; Loveleen Kang; Donna L Herber; Jonathan Schneck; Dmitry I Gabrilovich
Journal:  Nat Med       Date:  2007-07-01       Impact factor: 53.440

View more
  6 in total

1.  Feasibility and Efficacy of Partially Replacing Post-Transplantation Cyclophosphamide with Bendamustine in Pediatric and Young Adult Patients Undergoing Haploidentical Bone Marrow Transplantation.

Authors:  Emmanuel Katsanis; Baldassarre Stea; Kristen Kovacs; Laurel Truscott; Muhammad Husnain; Sharad Khurana; Denise J Roe; Richard J Simpson
Journal:  Transplant Cell Ther       Date:  2022-04-20

2.  Commentary: Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4+ T-Cell Proliferation and Differentiation After Murine MHC-Haploidentical Hematopoietic Cell Transplantation.

Authors:  Jessica Stokes; Richard J Simpson; Emmanuel Katsanis
Journal:  Front Immunol       Date:  2022-04-14       Impact factor: 8.786

3.  Murine precursors to type 1 conventional dendritic cells induce tumor cytotoxicity and exhibit activated PD-1/PD-L1 pathway.

Authors:  Megan S Molina; Emely A Hoffman; Jessica Stokes; Nicole Kummet; Richard J Simpson; Emmanuel Katsanis
Journal:  PLoS One       Date:  2022-08-18       Impact factor: 3.752

4.  Regulatory Dendritic Cells Induced by Bendamustine Are Associated With Enhanced Flt3 Expression and Alloreactive T-Cell Death.

Authors:  Megan S Molina; Emely A Hoffman; Jessica Stokes; Nicole Kummet; Kyle A Smith; Forrest Baker; Tiffany M Zúñiga; Richard J Simpson; Emmanuel Katsanis
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

5.  Bendamustine Conditioning Skews Murine Host DCs Toward Pre-cDC1s and Reduces GvHD Independently of Batf3.

Authors:  Megan S Molina; Jessica Stokes; Emely A Hoffman; Jelena Eremija; Yi Zeng; Richard J Simpson; Emmanuel Katsanis
Journal:  Front Immunol       Date:  2020-07-16       Impact factor: 7.561

6.  Bendamustine with total body irradiation conditioning yields tolerant T-cells while preserving T-cell-dependent graft-versus-leukemia.

Authors:  Jessica Stokes; Emely A Hoffman; Megan S Molina; Nicole Kummet; Richard J Simpson; Yi Zeng; Emmanuel Katsanis
Journal:  Oncoimmunology       Date:  2020-04-30       Impact factor: 8.110

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.